Chaps Vision

Navigating The Agentic Revolution in Life Sciences

Industry at a Crossroads

It currently costs up to
$2.6B
to bring a single drug to market

Approximately
90%
of drug candidates fail due to fragmented knowledge

The average drug spends
10-15 Years
getting from discovery to approval

Agentic AI is an imperative for competitive advantage

Agentic Adoption Reality Check

26%
of Life Sciences enterprises have **TRUE AGENTS** or **MULTI-AGENT** systems in production, compared to

78%
who believe they do due to agent-washing

Leading Use Cases

R&D and Drug Discovery (37%)

Clinical Operations (33%)

Massive ROI potential

Complex, data-rich processes

Accuracy is the Biggest Barrier

49%
cite accuracy as the top concern vs. 39% market-wide

40%
struggle with dynamic, multi-modal data needed to inform AI

38%
cite data silos as a top barrier to agentic adoption

Trust and Privacy are Top Concerns





If you can't trust the AI, it blocks high value use cases

A Roadmap For Life Sciences

1

Solve Connectivity Gap First

Invest in connectors and a unified knowledge layer across all siloed data over more in generic AI assistants.

2

Governance As Competitive Advantage

In LS, robust governance is a prerequisite for scale. Organizations with agent-specific policies are the ones moving into production the fastest.

3

Prioritize Value Over Scale

Don't just build more chatbots. Focus on high-value true agent use cases like Drug Discovery and Clinical Operations.

Download the State of Enterprise Agentic AI report

Download Now

www.chapsvision.com | www.sinequa.com